2.41
-0.0053(-0.22%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.34 |
| Day High | 2.49 |
| Day Low | 2.34 |
| 52-Week High | 4.98 |
| 52-Week Low | 1.02 |
| Volume | 70,613 |
| Average Volume | 147,112 |
| Market Cap | 22.05M |
| PE | -9.64 |
| EPS | -0.25 |
| Moving Average 50 Days | 2.59 |
| Moving Average 200 Days | 2.18 |
| Change | -0.01 |
If you invested $1000 in iBio, Inc. (IBIO) 10 years ago, it would be worth $0.72 as of December 26, 2024 at a share price of $2.41. Whereas If you bought $1000 worth of iBio, Inc. (IBIO) shares 5 years ago, it would be worth $20.96 as of December 26, 2024 at a share price of $2.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iBio Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire Inc.
Nov 25, 2024 1:00 PM GMT
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Direc
iBio Reports Fiscal First Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 12, 2024 9:05 PM GMT
Advanced myostatin program with dosing underway in non-human primate studySAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a cor
iBio and AstralBio Provide Update on Myostatin Program for Obesity
GlobeNewswire Inc.
Oct 10, 2024 12:00 PM GMT
Lead molecule identified with potential extended half-life and subcutaneous dosingSAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the my